Anthony Bourdain and Lewy Body Dementia
Anthony Bourdain died by suicide in June 2018 at age 61. His family confirmed that he had been suffering from Lewy body dementia, a progressive brain disorder. The announcement came shortly after his death, as reported by his representatives and public records. This form of dementia affects cognition, movement, behavior, and mood, and is often misdiagnosed or underrecognized. His case brought global attention to the condition and its impact on high-functioning individuals.
Lewy body dementia is the second most common type of degenerative dementia after Alzheimer's disease, affecting an estimated 1.4 million people in the United States alone, according to the Lewy Body Dementia Association. It is caused by abnormal deposits of a protein called alpha-synuclein in brain cells. These deposits, called Lewy bodies, disrupt chemical messengers involved in thinking, movement, behavior, and mood. Bourdain's publicist confirmed the diagnosis after his death, noting that he had experienced a decline in cognitive and physical function in his final months.
Symptoms, Stages, and Diagnosis of Lewy Body Dementia
Core Symptoms and Clinical Features
Key symptoms include fluctuating attention and alertness, repeated visual hallucinations, motor symptoms similar to Parkinson's disease such as stiffness and slowness, and REM sleep behavior disorder where people act out dreams. Cognitive decline in Lewy body dementia often involves problems with planning, problem-solving, and visual perception. Autonomic nervous system dysfunction can cause blood pressure drops, constipation, and bladder issues. These symptoms overlap with Alzheimer's and Parkinson's disease, making diagnosis challenging and often requiring specialist evaluation.
Diagnostic Criteria and Tools
Diagnosis is based on clinical assessment, medical history, and neurological exams. Imaging scans such as dopamine transporter SPECT scans can support the diagnosis by showing reduced dopamine transporters in the brain. There is no single definitive test during life, and many cases are confirmed only through autopsy. Bourdain's family did not release detailed medical records, but the clinical picture aligned with the core features of Lewy body dementia as defined by consensus guidelines from the Dementia with Lewy Bodies Consortium.
Current Research, Treatment, and Outlook for Lewy Body Dementia
Available Treatments and Management
Treatment focuses on managing symptoms rather than stopping disease progression. Cholinesterase inhibitors such as rivastigmine are commonly prescribed to improve cognition and alertness. Physical therapy, occupational therapy, and speech therapy help maintain mobility and communication skills. Non-pharmacological approaches like structured routines, environmental modifications, and caregiver support are central to care plans. Some medications used for Alzheimer's or psychiatric symptoms can worsen Lewy body dementia symptoms, requiring careful medical supervision.
Ongoing Research and Clinical Trials
Research into disease-modifying therapies is ongoing, with studies targeting alpha-synuclein aggregation and neuroinflammation. The National Institute on Aging and the Lewy Body Dementia Association fund and track clinical trials across multiple sites. Patients and families can search for trials on clinicaltrials.gov, which lists studies for dementia with Lewy bodies and related conditions. Bourdain's death highlighted the urgent need for better diagnostics, faster diagnosis timelines, and more effective treatments for this complex brain disorder.